Search
Influenza A virus A/Norway/16606/2021 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB16901ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza B virus B/Austria/1359417/2021 BVR-26 hemagglutinin antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16904ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Darwin/9/2021 SAN-010 (H3N2) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16916ApprovedThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB16918ApprovedWithdrawnThese vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Stem-cell derived exosome vesicle products
go.drugbank.com/drugs/DB15743ExperimentalOnce secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. … Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication.
Proxibarbal
go.drugbank.com/drugs/DB13253ApprovedProxibarbal was approved in France but was withdrawn from the market due to the risk of inducing immunoallergic thrombocytopenia [L5476].
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalPreviously, this drug was indicated only for patients with 17p gene deletion [F2130]. … A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Categories: Antihypertensive Agents Indicated for HypertensionAmylmetacresol
go.drugbank.com/drugs/DB13908ApprovedThe acute sore throat (pharyngitis) is one of the most common conditions for which children are seen in the primary care setting. … Pharyngitis is normally caused by viruses and proves benign and self-limiting.
Nedocromil
go.drugbank.com/drugs/DB00716ApprovedA pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Categories: Drugs for Obstructive Airway Diseases